{"filing":{"accession_number":"0001193125-26-406007","cik":"0001832038","ticker":"IVVD","company_name":"Invivyd, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"ivvd-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526406007/ivvd-20260929.htm"},"events":[{"id":35587,"run_id":32786,"accession_number":"0001193125-26-406007","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Invivyd announced positive Phase 3 topline results from the LIBERTY study demonstrating that VYD2311 met all primary and secondary endpoints with superior safety and tolerability compared to mRNA-based COVID-19 vaccine, and announced plans to submit a Biologics License Application (BLA) to the FDA via the Accelerated Approval Program. This is a material clinical milestone and regulatory development for an investigational drug candidate, but does not fit neatly into the specific event categories (not earnings, not M\u0026A, not a restatement, not a covenant breach, etc.). The disclosure centers on positive clinical trial results and regulatory pathway advancement, which are operational/strategic milestones for a biopharmaceutical company.","company_name":"Invivyd, Inc.","ticker":"IVVD","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39687,"accession_number":"0001193125-26-406007","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Invivyd announced positive Phase 3 topline results from the LIBERTY study demonstrating that VYD2311 met all primary and secondary endpoints with superior safety and tolerability compared to mRNA-based COVID-19 vaccine, and announced plans to submit a Biologics License Application (BLA) to the FDA via the Accelerated Approval Program. This is a material clinical milestone and regulatory development for an investigational drug candidate, but does not fit neatly into the specific event categories (not earnings, not M\u0026A, not a restatement, not a covenant breach, etc.). The disclosure centers on positive clinical trial results and regulatory pathway advancement, which are operational/strategic milestones for a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:27:39.025171+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39687,"accession_number":"0001193125-26-406007","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Invivyd announced positive Phase 3 topline results from the LIBERTY study demonstrating that VYD2311 met all primary and secondary endpoints with superior safety and tolerability compared to mRNA-based COVID-19 vaccine, and announced plans to submit a Biologics License Application (BLA) to the FDA via the Accelerated Approval Program. This is a material clinical milestone and regulatory development for an investigational drug candidate, but does not fit neatly into the specific event categories (not earnings, not M\u0026A, not a restatement, not a covenant breach, etc.). The disclosure centers on positive clinical trial results and regulatory pathway advancement, which are operational/strategic milestones for a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:27:39.025171+00:00","company_name":"Invivyd, Inc.","ticker":"IVVD","filing_date":"2026-09-29"}]}